Company news
Xbrane Biopharma Ab (OMXSTO:XBRANE) news
Xbrane Biopharma Ab news releases on 6ix. Latest, Jul 17, 2026: Xbrane Biopharma : releases Interim Report for January-June 2026
Press releases & updates
Xbrane Biopharma : releases Interim Report for January-June 2026
July 17, 2026
Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)
June 11, 2026
Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)
June 3, 2026
Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities
May 5, 2026
XBRANE SUBMITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
April 30, 2026
Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States
March 31, 2026
Xbrane has released the company's 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.
March 31, 2026
Xbrane Biopharma releases Year-end Report 2025
February 20, 2026
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution
November 24, 2025
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
November 19, 2025
Xbrane Enters Into Conditional Financing Deal Related To Ranibizumab Biosimilar
October 27, 2025
Xbrane Biopharma releases Interim Report for January-September 2025
October 24, 2025